Benitec Biopharma raises ~$30.9M gross in underwritten public offering; Series 2 warrants exercise price reset to $1.93

Benitec Biopharma Inc.

Offering included 875,949 common shares, 15.1M pre-funded warrants, 16.0M common warrants; net proceeds ~$28.3M.
Combined purchase price $1.93 per share/warrant unit; common warrants exercisable at $3.86 for 5 years.
Exercise price of 29.8M outstanding Series 2 warrants automatically reset from $11.22 to $1.93 due to offering.
Proceeds to support clinical development of BB-301 (Phase 1b/2a natural history and treatment studies) and other programs.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Benitec Biopharma Inc. entered into Underwriting Agreement with Citizens JMP Securities, LLC valued at approximately $28.3 million (effective 2023-08-08).

Action: entry
Agreement: underwriting
Counterparty: Citizens JMP Securities, LLC
Value: approximately $28.3 million
Effective: 2023-08-08

Exact text from the filing

On August 8, 2023, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Citizens JMP Securities, LLC (the “Underwriter”)

View on SEC.gov

115 material agreements filed in the last 30 days. Browse all material agreements →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-210679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.